David Y. Liu
Net Worth

Last updated:

What is David Y. Liu net worth?

The estimated net worth of Dr. David Y. Liu is at least $9,732,124 as of 16 Nov 2022. He owns shares worth $3,273,875 as insider, has earned $702,889 from insider trading and has received compensation worth at least $5,755,360 in Protagonist Therapeutics, Inc..

What is the salary of David Y. Liu?

Dr. David Y. Liu salary is $719,420 per year as Chief Scientific Officer and Head of Discovery & Pre-Clinical Devel. in Protagonist Therapeutics, Inc..

How old is David Y. Liu?

Dr. David Y. Liu is 75 years old, born in 1950.

What stocks does David Y. Liu currently own?

As insider, Dr. David Y. Liu owns shares in one company:

Company Title Shares Price per share Total value
Protagonist Therapeutics, Inc. (PTGX) Chief Scientific Officer and Head of Discovery & Pre-Clinical Devel. 58,254 $56.2 $3,273,875

What does Protagonist Therapeutics, Inc. do?

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

PTGX logo
PTGX
Protagonist Therapeutics, Inc.
$56.2

David Y. Liu insider trading

Protagonist Therapeutics, Inc.

Dr. David Y. Liu has made 12 insider trades between 2017-2022, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 35,656 units of PTGX stock on 16 Nov 2022. As of 16 Nov 2022 he still owns at least 58,254 units of PTGX stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 13,767 $0.87 $11,977
Option
Stock Option (right to buy) 35,331 $4.21 $148,744
Option
Common Stock 35,331 $4.21 $148,744
Option
Common Stock 35,656 $1.16 $41,361
Option
Common Stock 5,999 $1.89 $11,338
Option
Common Stock 9,726 $1.89 $18,382
Sale
Common Stock 14,779 $47.56 $702,889
Option
Stock Option (right to buy) 10,000 $0.87 $8,700
Option
Common Stock 10,000 $0.87 $8,700
Sale
Common Stock 3,395 N/A N/A
Sale
Common Stock 810 N/A N/A
Sale
Common Stock 3,821 N/A N/A
Sale
Common Stock 3,500 N/A N/A
Option
Common Stock 3,500 N/A N/A
Option
Employee Stock Option (right to buy) 3,500 N/A N/A
Sale
Common Stock 875 N/A N/A
Option
Common Stock 875 N/A N/A
Option
Employee Stock Option (right to buy) 875 N/A N/A
Sale
Common Stock 875 N/A N/A
Option
Common Stock 875 N/A N/A
Option
Employee Stock Option (right to buy) 875 N/A N/A
Option
Employee Stock Option (right to buy) 875 N/A N/A
Option
Common Stock 875 N/A N/A
Sale
Common Stock 875 N/A N/A
Sale
Common Stock 875 N/A N/A
Option
Employee Stock Option (right to buy) 875 N/A N/A
Sale
Common Stock 3,500 N/A N/A
Option
Common Stock 3,500 N/A N/A
Option
Employee Stock Option (right to buy) 7,000 N/A N/A
Sale
Common Stock 3,500 N/A N/A
Option
Common Stock 3,500 N/A N/A
Option
Employee Stock Option (right to buy) 3,500 N/A N/A
Option
Common Stock 3,500 N/A N/A
Option
Employee Stock Option (right to buy) 3,500 N/A N/A
Sale
Common Stock 3,500 N/A N/A

Protagonist Therapeutics key executives

Protagonist Therapeutics, Inc. executives and other stock owners filed with the SEC: